Please provide your email address to receive an email when new articles are posted on . Both guidelines begin with antihistamines. Guidelines in the US recommend further antihistamine use before ...

Last week, Celltrion USA announced it had submitted a BLA for CT-P39, a biosimilar to XOLAIR (omalizumab). Phase 3 studies demonstrated that in patients with chronic spontaneous urticaria, CT-P39 and ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...

Please provide your email address to receive an email when new articles are posted on . Omlyclo is the first interchangeable biosimilar to omalizumab (Xolair; Genentech, Novartis). Omlyclo was ...

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

BRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (AMRX) (“Amneal” or the “Company”) today announced the submission of a Biologics License Application (BLA) to the U.S ...

Amneal is expanding its portfolio with omalizumab, a proposed biosimilar of Novartis AG’s Xolair. Omalizumab is a humanized monoclonal antibody that targets free immunoglobulin E. It is an injectable ...

Patients with CSU have an elevated risk of anxiety and depression, necessitating comprehensive management strategies. Research is focused on identifying biomarkers and clinical characteristics to ...